fbpx Call for Late-Breaking Clinical Trials and Science | Heart Rhythm

Call for Late-Breaking Clinical Trials and Science

The Heart Rhythm Society recognizes that stimulating and rapidly developing research was not completed in time for the December 2025 abstract submission deadline. To highlight this timely, innovative work at Heart Rhythm 2026, the Heart Rhythm Program Committee will develop peer-reviewed sessions consisting of late-breaking science and late-breaking clinical trials.

Categories

  1. Late-Breaking Randomized Clinical Trials and Innovative Studies: First-time presentation of primary or major secondary results from a prospective, randomized clinical trial. First-time presentation of results of clinical applications of novel therapeutic or diagnostic approaches to heart rhythm disorders
     
  2. Late-Breaking Clinical Trial Updates and Registries: Follow-up analyses from prospective, randomized clinical trials or first-time presentation of high-impact information from multicenter clinical registries or observational studies
     
  3. Late-Breaking Science: Innovative research that includes the latest breakthroughs in basic and/or clinical science that could have a significant impact on clinical practice

Benefits of Presenting

  • Save on Registration: Late Breaking Trials and Science Presenters enjoy a 75% discount on their Heart Rhythm 2026 registration.*

  • Publish Your Science: Accepted submissions will be published in Heart Rhythm, the only academic publication that serves the entire EP community.

  • Advance Your Career: Among the EP community, the annual Heart Rhythm meeting is the recognized forum for showcasing research that will advance the field. Demonstrate your value and the impact of your findings to the audience that matters most to your professional development.

  • Increase Your Visibility:

    • Heart Rhythm 2026 will attract a diverse global audience from physicians and allied professionals to scientists and industry partners. As a selected Late Breaking Trials and Science Presenter, you will have the opportunity to present your findings to thousands of cardiac rhythm professionals from 90+ countries. With opportunities for attendees to watch in person or online via livestreaming, Late Breaking sessions are among the highest-viewed content from the meeting!

    • Additionally, you will be able to extend your reach via far-reaching media buzz. Heart Rhythm 2026 generated hundreds of millions of impressions worldwide via media outlets and social media.

*Already registered? If your late-breaking abstract is selected for presentation, HRS will refund the difference in your registration fees. If you are not registered at the time of being selected to present, your discount will automatically be applied at checkout when you register.

Submission Fees

Each late-breaking abstract submission requires a fee of $175 for HRS members and $275 for nonmembers. These submission fees directly fund travel grants to sponsor EP fellows-in-training from around the globe to attend Heart Rhythm 2026 in person, and support enhancements to the presentation of abstracts during the meeting.

Download the 2026 Late Breaking Submission Guidelines here for additional details, including author eligibility, withdrawal, and embargo policies.

If you have any questions, please email [email protected].

Submission Eligibility

Late-breaking abstracts are not eligible if:

  • Already accepted for Heart Rhythm 2026
  • Manuscript will be published prior to Heart Rhythm 2026 (April 23-26, 2026)
  • Trial results have been presented at a major international meeting prior to Heart Rhythm 2026
  • Appear to be redundant versions of a single study and/or selling a product versus discussing the science

Evaluation Criteria

  1. Impact of the research
  2. Novelty and rigor of the study design
  3. Clinical endpoints
  4. Quality of the statistical plan

Review Process

Late-breaking submissions are assigned to the Program Chair, Abstract Chair, President, President-Elect, and the Team Leads of the Program Committee for review. If any LBCT reviewers are listed as author/co-author on any of the submissions, they are not assigned that submission for review. The Late-breaking review process follows the same blind review standards as the general abstract review, ensuring that author information is not visible to reviewers. In addition, reviewers are asked to recuse themself from reviewing any submission for which they may have a conflict of interest. 

Once the above reviewers have reviewed all late-breaking submissions, the Abstract Chair* and Program Chair** will make the final selections. This includes determining (1) the 20 abstracts to be presented in traditional Late-Breaking Clinical Trial & Science (LBCT) sessions, (2) those selected as posters, and (3) those not accepted for presentation. In determining the final 20 selected late-breakers, the Abstract Chair and Program Chair also select a Commentator for each submission.

*In the event that the Abstract Chair is an author/co-author on any late-breaking submissions, they will recuse themself from making the final determinations, and the Program Chair will solely make the final selections.

**In the event that the Program Chair is an author/co-author on any late-breaking submissions, they will recuse themself from making the final determinations, and the Abstract Chair will solely make the final selections.

Important Embargo Dates

  • Friday, April 24, 2026 - 9:00 AM CT: LBCT Session #1 beginning at 10:00 AM CT 

  • Saturday, April 25, 2026 - 7:00 AM CT: LBCT Session #2  beginning at 8:00 AM CT

  • Saturday, April 25, 2026 - 10:00 AM CT: LBCT Session #3 beginning at 11:00 AM CT 

  • Sunday, April 26, 2026 - 7:30 AM CT: LBCT Session #4 beginning at 8:30 AM CT 

  • Sunday, April 26, 2026 - 10:30 AM CT: LBCT Session #5 beginning at 11:30 AM CT 

Frequently Asked Questions (FAQs)

Can I submit an abstract or case report if it has been presented previously?

Can I submit an abstract if it has been published previously?

Am I allowed to submit my abstract to other meetings or journals?

How do I include a table with my submission?

What is the character count for submission? What is included in the character count?

Do all authors have to be members of HRS?

Do all co-authors need to submit disclosures?

Is the first author the presenting author?

Can I change the author order in my submission?

Do you accept encore abstracts?

If my abstract is accepted, how and when will I be notified?

What is the fee for a LBCT submission?

How will I know if my submitted abstract is complete?

Can I make edits to my abstract after submission?

Does HRS have a policy for use of AI in submitted abstracts?

Who will be notified if the LBCT submission is accepted?

Do I need to get a signed patient consent form for my case submission?

What are the Embargo dates for general abstracts and LBCT's?